BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 37408838)

  • 1. The gut-liver axis in immune remodeling of hepatic cirrhosis.
    Guan H; Zhang X; Kuang M; Yu J
    Front Immunol; 2022; 13():946628. PubMed ID: 37408838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiota, cirrhosis, and the emerging oral-gut-liver axis.
    Acharya C; Sahingur SE; Bajaj JS
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of microbiome in patients with decompensated cirrhosis.
    Oikonomou T; Papatheodoridis GV; Samarkos M; Goulis I; Cholongitas E
    World J Gastroenterol; 2018 Sep; 24(34):3813-3820. PubMed ID: 30228776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases.
    Yang X; Lu D; Zhuo J; Lin Z; Yang M; Xu X
    Int J Biol Sci; 2020; 16(13):2357-2366. PubMed ID: 32760203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut-liver axis: Pathophysiological concepts and clinical implications.
    Tilg H; Adolph TE; Trauner M
    Cell Metab; 2022 Nov; 34(11):1700-1718. PubMed ID: 36208625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis.
    Woodhouse C; Singanayagam A; Patel VC
    Clin Med (Lond); 2020 Sep; 20(5):493-500. PubMed ID: 32934044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy
    Luo M; Xin RJ; Hu FR; Yao L; Hu SJ; Bai FH
    World J Gastroenterol; 2023 Jan; 29(1):144-156. PubMed ID: 36683714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
    Stecher B
    Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the gut-liver-immune axis to treat cirrhosis.
    Tranah TH; Edwards LA; Schnabl B; Shawcross DL
    Gut; 2021 May; 70(5):982-994. PubMed ID: 33060124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.
    Maslennikov R; Poluektova E; Zolnikova O; Sedova A; Kurbatova A; Shulpekova Y; Dzhakhaya N; Kardasheva S; Nadinskaia M; Bueverova E; Nechaev V; Karchevskaya A; Ivashkin V
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease.
    Maccioni L; Leclercq IA; Schnabl B; Stärkel P
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.
    Bajaj JS; Betrapally NS; Hylemon PB; Heuman DM; Daita K; White MB; Unser A; Thacker LR; Sanyal AJ; Kang DJ; Sikaroodi M; Gillevet PM
    Hepatology; 2015 Oct; 62(4):1260-71. PubMed ID: 25820757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
    Jiang JW; Chen XH; Ren Z; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered Microbiome in Patients With Cirrhosis and Complications.
    Acharya C; Bajaj JS
    Clin Gastroenterol Hepatol; 2019 Jan; 17(2):307-321. PubMed ID: 30099098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver cirrhosis and immune dysfunction.
    Hasa E; Hartmann P; Schnabl B
    Int Immunol; 2022 Sep; 34(9):455-466. PubMed ID: 35792761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.